RVMD stock forecast, quote, news & analysis
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers... Show more
Why Revolution Medicines (RVMD) Stock Is Up +14% in the Last 30 Days
Key Takeaways
- Revolution Medicines (RVMD) surged approximately 14% over the last 30 days, climbing from $156.58 on June 16 to $179.18 by July 16, 2026, driven by sustained momentum from landmark Phase 3 pancreatic cancer data.
- The broader quarterly trend underscores a powerful rally of roughly 20%, with shares advancing from around $149 in mid-April as the company's daraxonrasib program continued to deliver clinical and regulatory catalysts.
- Multiple Wall Street analysts raised price targets over the period — Guggenheim lifted its target to $235, Needham to $235, and Mizuho to $215 — reflecting growing conviction in an upcoming New Drug Application submission.
- The company remains pre-revenue with widening R&D expenses, yet holds over $1.9 billion in cash, providing substantial runway as it advances toward potential commercialization.
- Investor attention remains fixed on the FDA regulatory pathway, additional pipeline readouts, and the company's transition toward becoming a commercial-stage oncology player.
Revolution Medicines (RVMD) Company Overview and Market Position
Revolution Medicines is a late-stage clinical oncology company headquartered in Redwood City, California, focused on developing novel targeted therapies for RAS-addicted cancers. The company's proprietary tri-complex inhibitor platform is designed to target RAS proteins — historically considered "undruggable" — by creating druggable binding sites that block oncogenic signaling. Its lead candidate, daraxonrasib (RMC-6236), is a RAS(ON) multi-selective inhibitor that has demonstrated unprecedented survival benefits in metastatic pancreatic ductal adenocarcinoma (PDAC). The pipeline also includes zoldonrasib (RMC-9805), a G12D-selective inhibitor; elironrasib (RMC-6291), a G12C-selective inhibitor; and RMC-5127, a G12V-selective inhibitor. With a market capitalization of approximately $40 billion and institutional ownership exceeding 94%, RVMD has emerged as one of the most closely watched names in the oncology biotech sector.
Revolution Medicines (RVMD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RVMD shares advanced from a closing price of $156.58 on June 16, 2026, to $179.18 on July 16, 2026 — a gain of roughly 14.4%. The stock demonstrated considerable resilience during this window, recovering from an intra-period dip near $141 in early June to reach a 52-week high of $193.10 in late June, before settling into a consolidation range in the $180–$190 zone. The 50-day simple moving average sits at approximately $156, while the 200-day moving average remains near $121, underscoring the strength and duration of the uptrend.
Zooming out to the full quarter, the performance is even more striking. From a close of $149.27 on April 16, 2026, the stock climbed approximately 20% to its mid-July level. This quarterly rally was fueled by the cascade of positive clinical developments — starting with the April announcement of positive topline Phase 3 RASolute 302 results, followed by the detailed ASCO plenary presentation on May 31 and simultaneous publication in The New England Journal of Medicine. Year-to-date, RVMD has surged nearly 140%, transforming from a sub-$50 stock at the start of 2026 into a $40-billion-plus market cap biotech.
What Drove RVMD Stock Price in the Last 30 Days
Several catalysts converged to propel RVMD shares higher during the trailing 30-day period. The most significant was the sustained aftermath of the ASCO 2026 plenary presentation, where detailed Phase 3 RASolute 302 data showed daraxonrasib delivering a median overall survival of 13.2 months versus 6.7 months for standard chemotherapy — a 60% reduction in the risk of death. Published simultaneously in The New England Journal of Medicine, the results solidified clinical credibility and fueled expectations that an NDA submission to the FDA under the Commissioner's National Priority Voucher program is imminent, potentially compressing the review timeline to one to two months.
Analyst activity played a reinforcing role. On June 29, Needham raised its price target from $183 to $235, and Truist lifted its target to $210 on June 30. Guggenheim followed on July 9, raising its target from $205 to $235 while maintaining a Buy rating. These revisions reflected growing confidence that daraxonrasib is on track to become the new standard of care in previously treated metastatic pancreatic cancer. Institutional activity remained robust, and the company's initiation of an Expanded Access Program for daraxonrasib further underscored the drug's perceived clinical value. The broader biotech sector also benefited from a rotation into high-growth, innovation-driven names during the period.
What Drove RVMD Stock Performance Over the Last Quarter
The quarterly narrative for RVMD was dominated by a series of high-impact clinical and regulatory milestones. In April 2026, Revolution Medicines announced that the RASolute 302 trial had met all primary and secondary endpoints at interim analysis, sending shares sharply higher. This was followed by the AACR 2026 presentations, which highlighted additional data on daraxonrasib in both monotherapy and chemotherapy combination settings in first-line PDAC. The crescendo arrived on May 31 at ASCO, where the full dataset — including patient-reported outcome improvements and quality-of-life measures — was unveiled to standing ovations.
Regulatory momentum built steadily. The FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for daraxonrasib, selected the program for the Commissioner's National Priority Voucher pilot, and authorized an Expanded Access Program. The European Medicines Agency also issued a positive opinion on Orphan Drug Designation. Meanwhile, Revolution Medicines raised $2.1 billion in net financing proceeds to support commercialization preparations and ongoing pipeline development. These events collectively transformed RVMD from a clinical-stage biotech with promising early data into a company widely perceived as standing at the threshold of approval and revenue generation.
Trending AI Robots
For traders seeking to navigate fast-moving stocks like RVMD with a data-driven edge, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. While Tickeron hosts hundreds of AI-powered bots trading across thousands of tickers, only those demonstrating the strongest and most relevant performance metrics are featured in this section. These bots employ diverse strategies, timeframes, and risk profiles — from short-term swing trading to longer-duration trend-following models — enabling users to explore approaches aligned with their individual trading styles. Whether markets are rallying on clinical breakthroughs or consolidating after major moves, the Trending AI Robots section provides a practical starting point for discovering AI-driven trading tools.
RVMD Stock Forecast Drivers: What Investors Should Watch Next
The most consequential near-term catalyst for RVMD is the formal submission of the daraxonrasib New Drug Application to the FDA. Under the Commissioner's National Priority Voucher program, the review period could be compressed to as little as one to two months, meaning a regulatory decision may arrive rapidly once the filing is accepted. Investors should also monitor enrollment progress and any interim readouts from the RASolute 303 trial in first-line metastatic PDAC, the RASolute 304 adjuvant trial, and the RASolve 301 study in non-small cell lung cancer. Later in 2026, early-stage colorectal cancer combination data are expected. On the financial side, continued R&D spending and widening losses are anticipated for a pre-commercial biotech of this scale. Competitive dynamics in the RAS inhibition space — including programs from BMY and other collaborators — also warrant attention. Insider selling activity, which totaled roughly $39 million over the last 90 days, adds a note of caution for some market participants.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RVMD's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for RVMD moved out of overbought territory on July 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RVMD as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RVMD turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
RVMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 263 cases where RVMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RVMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.445) is normal, around the industry mean (20.985). P/E Ratio (0.000) is within average values for comparable stocks, (37.521). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). RVMD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (422.678).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology company, which focused on developing novel targeted therapies and engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment.
Industry Biotechnology